ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO155

AMPK Activation Protects Kidney Function After Renal Ischemia Reperfusion Injury in Rats

Session Information

  • AKI: Mechanisms - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Frikke-Schmidt, Henriette, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Albarazanji, Kamal Ahmed, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Qi, Jenson, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Frederick, David, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Du, Fuyong, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Meng, Rong, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Ho, George, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Nawrocki, Andrea R., Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Pocai, Alessandro, Janssen Research and Development LLC, Spring House, Pennsylvania, United States

Group or Team Name

  • Cardiovascular, Metabolism, Retina and Pulmonary Hypertension Therapeutic Area.
Background

The kidney has a high energy demand to carry out its function, and with Acute Kidney Injury (AKI) such as ischemia reperfusion, there is profound mitochondrial damage. Adenosine Monophosphate Kinase (AMPK) is a key regulator of mitochondrial function and biogenesis. Here, we used a rat model of ischemia-reperfusion inducing AKI to explore the effect of pharmacological activation of AMPK.

Methods

Male Spraque Dawley rats were treated with a direct AMPK activator (n=12) or vehicle (n=12) one hour prior to ischemia reperfusion induced by bilateral clamping the renal pedicles for 35 minutes. Kidney functions was assessed by transcutaneous glomerular filtration rate (tGFR) measured at 5-7 hours using the Medibeacon technology, and kidney, plasma and urine were collected for analysis of plasma creatinine, urinary NephroCheck and kidney histology 7 hours post injury.

Results

Plasma creatinine and tGFR were significantly improved in the animals treated with AMPK activator compound compared to vehicle control with a 28% reduction of creatinine (1.53±0.257 versus 1.10±0.184 mg/dl, p<0.001) and 69% improvement in tGFR (0.0792± 0.0452 versus 0.135±0.0738 ml/min/100g bodyweight, p<0.05). AMPK activation improved urinary NephroCheck score (0.0764±0.0564 versus 0.00899±0.00356 (ng/ml)2/1000 of IGFBP7 and TIMP2, p<0.001) and acute tubular necrosis in the cortex.

Conclusion

Pharmacological activation of AMPK alleviated kidney function and preserved tubular structure. These data support AMPK activation as a novel therapeutic approach for AKI.

Funding

  • Commercial Support – Janssen R&D